PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows (NASDAQ:PTCT)
· seekingalpha.com
PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price.
Sephience, PTC Therapeutics, Inc. ( PTCT )’s drug for phenylketonuria (PKU), was approved in the US in July 2025 and is currently PTC’s main source of growt...